[6] Although the role of other cell types in GATA3 expression remains a subject of ongoing debate, the targeting of GATA3 using DNAzyme technology as a potential asthma treatment has successfully advanced through Phase 2b clinical trials. The gene discussed is GATA3; the disease is asthma.